|
131 |
Switching From Originator to Biosimilar Human Growth Hormone Using Dialogue Teamwork: Single-Center Experience From Sweden Enthalten in Biologics in therapy Bd. 3, 28.5.2013, Nr. 1, date:6.2013: 35-43
|
|
|
132 |
The Frequency of Ovarian Hyperstimulation Syndrome and Thromboembolism with Originator Recombinant Human Follitropin Alfa (GONAL-f) for Medically Assisted Reproduction: A Systematic Review Enthalten in Advances in therapy Bd. 37, 15.10.2020, Nr. 12, date:12.2020: 4831-4847
|
|
|
133 |
The Nocebo Effect in a Non-Medical Switching Program from Originator to Biosimilar Infliximab in Inflammatory Bowel Disease Enthalten in BioDrugs Bd. 36, 12.8.2022, Nr. 5, date:9.2022: 639-644
|
|
|
134 |
To the Editor; A Commentary on “Switching From Originator to Biosimilar Human Growth Hormone Using a Dialogue Teamwork: Single-Center Experience From Sweden” Enthalten in Biologics in therapy Bd. 4, 23.4.2014, Nr. 1-2, date:12.2014: 69-71
|
|